Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025 ...

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Novo Nordisk (NVO – Research Report) yesterday and set a price target of ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Struggling with plunging demand for its COVID products, Pfizer Inc., which has facility ... LillyDirect portal to sell popular obesity and diabetes treatments, marking the first time a major ...

The Florida Department of Health, run by Surgeon General Dr. Joseph Ladapo, just released guidance on COVID-19 vaccines based ...

These include being over 65 years of age, having a health condition, such as heart disease, diabetes ... and manufacture of health care products, including innovative medicines and vaccines. Every day ...

Replacing 10 percent of ultra-processed foods with healthier alternatives lowered diabetes risk by up to 18 percent, a new study says.

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Pfizer is advancing on a broad front in its ... for its oral semaglutide – already approved as Rybelsus for type 2 diabetes and with a filing in obesity due this year – and it also has early ...

A decade of patient follow-up finds a combo of two immunotherapy drugs can greatly extend survival for people with advanced ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes ... and the two fixed-dose combination products in the US. Merck and Pfizer will share potential revenues ...